Weekly Update | 19–25 September 2026

DRAFT FOR REVIEW — DO NOT PUBLISH. Update verified against primary sources available through 25 September 2026.

Editorial category: Evidence Update
Coverage period: 19–25 September 2026
Last verified: 25 September 2026
Updates selected: 1 phase III study with potentially high impact

At a glance

This week’s search identified only one development meeting the prespecified thresholds for evidence quality and clinical relevance: a phase III randomized trial of rabies post-exposure prophylaxis.
In 1,200 adults with suspected World Health Organization (WHO) category III exposure, the bispecific monoclonal antibody silevimig was non-inferior to human rabies immunoglobulin for the early neutralizing-antibody response.
This is neither a new guideline nor a European authorization; it does not change current Italian practice today.
No other sufficiently robust official update or practice-changing study was identified in the main emergency medicine domains during the covered period.

1. Silevimig for rabies post-exposure prophylaxis

Source and date: Wang X, He J, Zha Y, et al. Comparison of Silevimig, a Novel Bispecific Anti-Rabies Monoclonal Antibody, with Human Rabies Immunoglobulin for Post-Exposure Prophylaxis: A Phase III, Randomized, Double-Blind, Non-Inferiority Trial. Clinical Infectious Diseases. Published online 21 September 2026. doi:10.1093/cid/ciag551.

What has changed

The trial adds phase III evidence for silevimig, a bispecific monoclonal antibody targeting two antigenic sites on the rabies virus, as a possible alternative to human rabies immunoglobulin for passive prophylaxis. This advances the evidence base but is not a formal recommendation change.

CURRENT STANDARD → NEW EVIDENCE: meticulous wound cleansing + rabies vaccine + rabies immunoglobulin when indicated → the same pathway, but silevimig replaced immunoglobulin in the trial and produced a non-inferior early immune response. Until regulatory and guideline adoption occurs, the standard does not change.

Population and setting

This was a multicentre, randomized, double-blind, non-inferiority trial. It enrolled 1,200 adults older than 18 years with suspected WHO category III rabies exposure, randomized 3:1 to silevimig or human rabies immunoglobulin. After wound cleansing, passive treatment was given on day 0 together with rabies vaccine on days 0, 3, 7, 14 and 28.

Essential numerical results

Adjusted geometric mean concentration of rabies virus-neutralizing antibodies on day 7: 0.40 IU/mL with silevimig versus 0.36 IU/mL with immunoglobulin.
Between-group ratio: 1.11; 95% confidence interval 1.01–1.21; the non-inferiority criterion was met.
No rabies cases occurred during one-year follow-up: rabies-free survival was 100% in both groups.
Serologic response rates on days 14 and 90 were slightly higher with silevimig; most adverse events were mild or moderate.

Evidence quality and limitations

Quality: a large phase III randomized, controlled, double-blind trial using an active comparator and a prespecified non-inferiority margin. Limitations: adults only; recruitment was concentrated in centres in China’s Yunnan Province, so generalisability needs confirmation; 3:1 randomization; and the discriminating outcome was mainly immunologic because clinical rabies is rare after correct prophylaxis and no cases occurred in either group. The study does not demonstrate clinical superiority, does not establish effectiveness in children or immunocompromised patients, and does not replace European regulatory review.

Why it matters in the ED/EMS

The emergency department may be the first point of care after a bite, scratch or mucosal contact with saliva from a potentially infected animal. A future monoclonal alternative could reduce dependence on, variability in and availability problems associated with human-derived immunoglobulin. For now, the operational priorities remain recognizing the exposure, cleansing and irrigating the wound thoroughly, avoiding delay in indicated prophylaxis, and promptly activating infectious-disease and public-health pathways according to local protocols.

Does this change the algorithm today?

NO. This is a single non-inferiority trial, not a formal recommendation. Publication does not equal availability or authorization in Italy. Silevimig should not independently replace the immunoglobulin required by local protocols.

Applicability in Italy

Current applicability: limited. The result matters for future planning and for centres managing rabies prophylaxis, but it does not justify a treatment change before authorization, availability, regulatory positioning and incorporation into national or regional protocols. For suspected exposure, follow the institutional pathway and public-health/infectious-disease guidance without waiting for further editorial confirmation.

No other robust change this week

Review of the main institutional, regulatory and peer-reviewed sources identified no new guideline, consensus statement, safety alert or sufficiently robust practice-changing trial published between 19 and 25 September 2026 that should alter current algorithms in resuscitation and post-cardiac arrest care; acute coronary syndromes and electrocardiography; arrhythmias; stroke and neurologic emergencies; trauma and haemorrhage; shock and sepsis; respiratory failure, oxygen therapy and non-invasive ventilation; thromboembolism; toxicology; point-of-care ultrasound; paediatric and obstetric emergencies; analgesia, sedation and airway management; or other time-critical pathways. Abstracts, preprints, commentaries and promotional reports were excluded.

Apply now

No new drug, dose, threshold or algorithm change arises from this week’s literature.
Maintain reliability of the existing rabies pathway: immediate wound cleansing, correct exposure classification and timely prophylaxis under the local protocol.

Discuss with the team

Where and how rabies vaccine and immunoglobulin can be obtained rapidly out of hours.
Who to contact in real time across infectious diseases, public health and the regional referral centre.
How to document the animal species, exposure location, wound depth, mucosal contamination and previous vaccination status.

Do not change yet

Do not replace rabies immunoglobulin with silevimig outside authorized availability and approved protocols.
Do not modify the local vaccine schedule on the basis of this study.
Do not automatically extrapolate the results to children, pregnancy, immunocompromised patients or exposure categories other than the category III population studied.

Three sources to read in full

Last verification date

25 September 2026 — EmergMemo editorial review.

Clinical note. This content is for informational and educational purposes. It does not replace local protocols, clinical assessment, professional judgement or current official guidelines. Always verify indications, dosages, contraindications, availability and primary sources.